Activating mutations in PIK3CA are among the most common somatic point mutations in cancer, together with inactivation or loss of the tumor suppressor PTEN, a negative regulator of class I phosphoinositide 3-kinase (PI3K) enzymes [1–3]. This evidence concerns the gene PIK3CA and cancer.